2Waddell T, Chau I, Cunningham D, et al. Epirubicin, ox- aliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesopha- gogastric cancer (REAL3): a randomised, open-label phase 3 trial[J]. Lancet Oncol, 14(6): 481-489.
3Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International col- laborative analysis[J]. Ann Oncol, 2012, 23(10): 2656- 2662.
4Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive ad- vanced gastric or gastro-oesophageal junction cancer (To- GA): a phase 3, open-label, randomised controlled trial [J]. Lancet, 2010, 376(9742): 687-697.
5Satoh T, Xu RH, Chung HC, et al. Lapatinib plus pacli- taxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase HI study[J]. J Clin Oncol, 2014, 32(19): 2039-2049.
6Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combina- tion with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC)[J]. J Clin Oncol. 2013, 31(18 Suool): LBA4001.
7Janjigian YY, Ku GY, Ilson DH, et al. A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab re- fractory esophagogastric (EG) cancer[J]. J Clin Oncol, 2015, 33(3 Suppl): 59.
8Barok M, Tanner M, Ktininki K, et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer[J]. Cancer Lett, 2011, 306(2): 171-179.
9Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with pre- viously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J]. Lancet Oncol, 2013, 14(6): 490-499.
10Du F, Zheng Z, Shi S, et al. S-1 and cisplatin with or without nimotuzumab for patients with untreated unre- sectable or metastatic gastric cancer: a randomized, open- label phase 2 trial[J]. Medicine (Baltimore), 2015, 94(23): E958.
